


NOVEL FORMULATIONS FOR OPIOID-BASED TREATMENTS OF PAIN
COMPRISING 1-(1,2-DISUBSTITUTED PIPERIDINYL)-4-SUBSTITUTED
PIPERAZINE DERIVATIVES

5 This invention concerns novel formulations for opioid-based treatments of pain
and/or nociception comprising opioid analgesics and 1-(1,2-disubstituted piperidinyl)-
4-substituted piperazine derivatives having neurokinin antagonistic activity, in
particular NK₁ antagonistic activity the use of said formulation for the manufacture of a
10 medicament for the prevention and/or treatment of emesis, pain and/or nociception, in
particular in acute and chronic pain treatments, more in particular in inflammatory,
post-operative, emergency room (ER), breakthrough, neuropathic and cancer pain
treatments and the use of an NK₁-receptor antagonist for the manufacture of a
medicament for the prevention and/or treatment of respiratory depression and tolerance
15 in opioid-based treatments of pain.

The pharmaceutical formulations according to the invention comprise NK₁-
antagonists according to the general Formula (I)



20 the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically
isomeric forms thereof, the *N*-oxide form thereof and prodrugs thereof, wherein all
substituents are defined as in Claim 1.

25 The pharmaceutical composition according to the invention reduces to a large
extent a number of unwanted side-effects associated with opioid analgesics, in
particular respiratory depression and tolerance, thereby increasing the total tolerability
of said opioids in pain treatment.